PTC Therapeutics Outlines Growth Strategy Amid Revenue Challenges

PTC Therapeutics (PTCT) presented its financial outlook and growth strategy at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, emphasizing disciplined operations and a diversified pipeline to offset revenue declines. The company, with over $2 billion in cash reserves, remains on track to achieve cash-flow breakeven in 2026, despite a 43% year-over-year drop in revenue to $1.01 billion over the prior 12 months. Analysts project a further 26% decline in current-year sales, reflecting maturing therapies and competitive pressures in biotechnology.